SOUTH SAN FRANCISCO, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer and eye diseases, will report
third quarter 2009 results on Monday, November 9th, 2009. A conference call and
webcast hosted by OXiGENE management will begin at 9:00 a.m. EST (6:00 a.m.
PST).
To listen to a live or archived version of the audio webcast, please log on to
the Company's website, www.oxigene.com. Under the "Investor" tab, select the
link to "Events and Presentations".
OXiGENE's earnings conference call can also be heard live by dialing
888-504-7949 in the United States and Canada, and 719-325-2215 for
international callers, five minutes prior to the beginning of the call. A
replay will be available starting at 12:00 p.m., EST (9:00 a.m., PST) on
November 3, 2009 and ending at 12:00 midnight EST (9:00 p.m., PST) on Monday,
November 23rd, 2009. To access the replay, please dial (888) 203-1112 if
calling from the United States or Canada, or (719) 457-0820 from international
locations. Please refer to replay pass code 4502965.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The Company's major focus is
developing vascular disrupting agents (VDAs) that selectively disrupt abnormal
blood vessels associated with solid tumor progression and visual impairment.
OXiGENE is dedicated to leveraging its intellectual property and therapeutic
development expertise to bring life-extending and life-enhancing medicines to
patients.
The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969
CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
medwards@oxigene.com
OXiGENE Announces Third Quarter 2009 Earnings Conference Call and Webcast
| Quelle: Oxigene, Inc.